Why the study?
Cardiovascular disorders are the leading cause of death worldwide, and extracellular vesicles hold therapeutic potential as natural drug delivery carriers and biomarkers across different disease states.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
EVs may indicate pathological progression as biomarkers; leaves open therapeutic translation in cardiovascular trials.
Due to their different biological functions, extracellular vesicles (EVs) have great potential from a therapeutic point of view. They are released by all cell types, carrying and delivering different kinds of biologically functional cargo. Under pathological events, cells can increase their secretion of EVs and can release different amounts of cargo, thus making EVs great biomarkers as indicators of pathological progression. Moreover, EVs are also known to be able to transport and deliver cargo to different recipient cells, having an important role in cellular communication. Interestingly, EVs have recently been explored as biological alternatives for the delivery of therapeutics, being considered natural drug delivery carriers. Because cardiovascular disorders (CVDs) are the leading cause of death worldwide, in this review, we will discuss the up-to-date knowledge regarding the biophysical properties and biological components of EVs, focusing on myocardial infarction, diabetic cardiomyopathy, and sepsis-induced cardiomyopathy, three very different types of CVDs.
No takes yet. Share an insight, caveat, or question.
Francés et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: